Julie L. Gerberding Merck & Co., Inc. (MRK) insider trading activity

Julie L. Gerberding is EVP, Chief Patient Officer of Merck & Co., Inc.. Currently has a direct ownership of 48,712 shares of MRK, which is worth approximately $5.71 Million. The most recent transaction as insider was on Feb 24, 2022, when has been sold 9,550 shares (Common Stock) at a price of $73.51 per share, resulting in proceeds of $702,021. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 48.7K

0% 3M change

0% 12M change

Total Value Held $5.71 Million

Julie L. Gerberding Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 24 2022	BUY Grant, award, or other acquisition	$702,021 $73.51 p/Share	9,550 Added 16.39%	48,712 Common Stock
Nov 01 2021	SELL Open market or private sale	$8,463,096 $87.91 p/Share	96,270 Reduced 71.08%	39,162 Common Stock
Nov 01 2021	BUY Exercise of conversion of derivative security	-	96,270 Added 41.55%	135,432 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	$913,923 $72.62 p/Share	12,585 Added 24.32%	39,162 Common Stock
Jul 17 2020	SELL Open market or private sale	$2,903,163 $80.01 p/Share	36,285 Reduced 57.72%	26,577 Common Stock
Jul 17 2020	BUY Exercise of conversion of derivative security	-	18,111 Added 22.37%	62,862 Common Stock
Feb 28 2020	BUY Grant, award, or other acquisition	$564,324 $76.56 p/Share	7,371 Added 14.24%	44,409 Common Stock
Jan 13 2020	SELL Open market or private sale	$9,119,201 $89.34 p/Share	102,073 Reduced 73.38%	37,038 Common Stock
Jan 13 2020	BUY Exercise of conversion of derivative security	-	82,548 Added 37.24%	139,111 Common Stock
Feb 25 2019	BUY Grant, award, or other acquisition	$703,084 $80.38 p/Share	8,747 Added 13.66%	55,287 Common Stock
Nov 07 2018	SELL Open market or private sale	$2,721,420 $75.14 p/Share	36,218 Reduced 43.91%	46,262 Common Stock
Nov 07 2018	BUY Exercise of conversion of derivative security	$1,980,400 $54.68 p/Share	36,218 Added 30.51%	82,480 Common Stock
May 15 2018	SELL Open market or private sale	$594,930 $59.66 p/Share	9,972 Reduced 17.91%	45,716 Common Stock
Feb 27 2018	BUY Grant, award, or other acquisition	$495,873 $54.72 p/Share	9,062 Added 14.08%	55,276 Common Stock
May 02 2017	SELL Payment of exercise price or tax liability	$67,246 $62.38 p/Share	1,078 Reduced 2.32%	45,338 Common Stock
May 02 2017	BUY Exercise of conversion of derivative security	-	3,092 Added 6.25%	46,416 Common Stock
Feb 27 2017	BUY Grant, award, or other acquisition	$244,106 $65.85 p/Share	3,707 Added 7.93%	43,062 Common Stock
Nov 07 2016	SELL Open market or private sale	$5,133,090 $60.02 p/Share	85,523 Reduced 68.62%	39,115 Common Stock
Nov 07 2016	BUY Exercise of conversion of derivative security	$3,444,866 $40.28 p/Share	85,523 Added 40.69%	124,638 Common Stock
May 06 2016	SELL Payment of exercise price or tax liability	$84,705 $54.09 p/Share	1,566 Reduced 3.89%	38,654 Common Stock
May 06 2016	BUY Exercise of conversion of derivative security	-	4,002 Added 9.05%	40,220 Common Stock
Feb 22 2016	BUY Grant, award, or other acquisition	$171,450 $50.77 p/Share	3,377 Added 8.58%	35,986 Common Stock
May 08 2015	SELL Open market or private sale	$2,340,064 $60.99 p/Share	38,368 Reduced 54.54%	31,985 Common Stock
May 08 2015	BUY Exercise of conversion of derivative security	$1,618,666 $35.03 p/Share	46,208 Added 39.64%	70,353 Common Stock
May 02 2015	SELL Payment of exercise price or tax liability	$72,670 $59.86 p/Share	1,214 Reduced 4.79%	24,145 Common Stock

Also insider at

HLVX

HilleVax, Inc. Healthcare

Director

JLG